Cytori Therapeutics is a specialty pharmaceutical company focused on addressing unmet medical and market needs with its cell therapy and nanomedicine platforms. Habeo™ Cell Therapy for scleroderma associated hand dysfunction, prepared using the Celution® System, is Cytori’s lead product candidate and is under evaluation in both US and French Phase III clinical trials. Cytori Cell Therapy™ is also being studied for thermal burns, knee osteoarthritis, and stress urinary incontinence in the US and Japan. Cytori’s lead nanomedicine product candidate is ATI-0918, a generic liposomal formulation of doxorubicin hydrochloride for breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma. ATI-1123 is also being developed as a next-generation, liposomal formulation of docetaxel. Through constantly balancing a blend of creativity, rigor, focused energy, and agility, Cytori delivers meaningful results that create exceptional value for our patients, partners, employees, shareholders, and society.

About Cytori Therapeutics

Cytori Therapeutics, Inc. is dedicated to developing and delivering innovative cell-based therapies to improve the quality and length of life. We are a global, public company engaged in the development and commercialization of stem and regenerative cell therapies for the treatment of cardiovascular disease, reconstructive surgery and many
 – more... 

Claimed Profile
Cytori Therapeutics website


Post a job- your next hire is here.